Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

Q3 · MEDICINE

ArticleOA

Author: Herrera, Luis ; Baladrón, Idania ; Bover, Eddy ; Vela, Idania ; Fernández, Luis E ; Campal, Ana ; López, Matilde ; Valenzuela, Carmen ; Cedeño, Pável ; González, Lourdes ; Capote, Carlos ; Guillén, Gerardo ; Fuentes, Franklin ; Medina, María ; Martínez, Carolina ; Calzada, Lesvia ; Cosme, Karelia ; de Quesada, Lourdes ; Porres-Fong, Liliana ; Ramirez, Amilcar ; Molero, Guillermo ; Alvarez, Allelin ; Rodríguez, Ayni ; Feria, Indalecio ; Garay, A Hilda ; Basulto, Roberto ; Sánchez, María Carmen ; Acosta, Sahily ; Reyes, Osvaldo ; Fernández, Yairis ; Rubio, Elier ; Marrero, Marleny ; Arzuaga, Lina ; Rodríguez, Ranfis ; Junco, Jesús A ; Ayala, Marta ; Muzio, Verena ; Cardoso, Pedro ; Rosales, Pedro ; Carr, Adriana ; Guerra, Alfredo ; Ruiz, Erlán ; Morán, Rolando ; Cid-Arregui, Angel ; Sariol, Francisco ; Bringas, Ricardo ; Touduri, Henio ; Castro, Maria D ; Quintana, Maricel ; Mendoza, Mario ; Bacardi, Dania ; Campos, Magalys ; Pimentel, Eulogio ; Saura, Pedro López ; Arteaga, Niurka

Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRHm1-TT peptide as the main active principle; 245 μg of the very small size proteoliposomes adjuvant (VSSP); and 350 μL of Montanide ISA 51 VG oil adjuvant. The aim of this study was to assess the safety and tolerance of the Heberprovac in advanced prostate cancer patients as well as its capacity to induce anti-GnRH antibodies, the subsequent effects on serum levels of testosterone and PSA and the patient overall survival. The study included eight patients with histologically-proven advanced prostate cancer with indication for hormonal therapy, who received seven intramuscular immunizations with Heberprovac within 18 weeks. Anti-GnRH antibody titers, testosterone and PSA levels, as well as clinical parameters were recorded and evaluated. The vaccine was well tolerated. Significant reductions in serum levels of testosterone and PSA were seen after four immunizations. Castrate levels of testosterone were observed in all patients at the end of the immunization schedule, which remained at the lowest level for at least 20 months. In a 10-year follow-up three out of six patients who completed the entire trial survived. In contrast only one out eight patients survived in the same period in a matched randomly selected group receiving standard anti-hormonal treatment. Heberprovac vaccination showed a good security profile, as well as immunological, biochemical and, most importantly, clinical benefit. The vaccinated group displayed survival advantage compared with the reference group that received standard treatment. These results warrant further clinical trials with Heberprovac involving a larger cohort.

100 Deals associated with Heberprovac

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	-	International Centre for Genetic Engineering and Biotechnology (ICGEB)	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Heberprovac

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation